The markets closed lower with the Dow dropping 51 points to 18,086 as crude oil prices slipped. Nasdaq fell 14 points to 5,199.
On the upside
ContraVir (Nasdaq: CTRV) has begun enrolling the next dosing group in its head-to-head Phase 2a dose-escalation study of CMX157 to treat chronic hepatitis B.
Sophiris Bio (Nasdaq: SPHS) will present at the 2016 BIO Investor Forum tomorrow.
Bargain hunters lifted shares of Ocean Power Technologies (Nasdaq: OPTT).
On the downside
Shares of Corbus Pharmaceuticals (Nasdaq: CRBP) extended its losses.
The Food and Drug Administration will withdraw its approval of Lannett's (NYSE: LCI) generic attention deficit disorder treatment.
Opus Bank (Nasdaq: OPB) warned that loan charge-offs will negatively impact third quarter earnings.
In the broad market, declining issues outpaced advancers by a margin of nearly 3 to 2 on the NYSE and by more than 7 to 5 on Nasdaq. The broader S&P 500 fell 6 points to 2,126. Bitcoin lost $1 to $636.
